Adamas Pharmaceuticals Inc (NASDAQ:ADMS) insider Jennifer J. Rhodes sold 440 shares of the stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $32.30, for a total value of $14,212.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Adamas Pharmaceuticals Inc (ADMS) traded up $0.33 on Thursday, hitting $32.23. The stock had a trading volume of 797,600 shares, compared to its average volume of 550,897. Adamas Pharmaceuticals Inc has a 12 month low of $13.50 and a 12 month high of $38.22. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.03). During the same quarter in the prior year, the company earned ($0.66) earnings per share. Adamas Pharmaceuticals’s quarterly revenue was down 99.3% compared to the same quarter last year. sell-side analysts predict that Adamas Pharmaceuticals Inc will post -3.84 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Adamas Pharmaceuticals in the third quarter valued at approximately $110,000. Quantbot Technologies LP bought a new stake in shares of Adamas Pharmaceuticals in the third quarter valued at approximately $119,000. Tower Research Capital LLC TRC bought a new stake in shares of Adamas Pharmaceuticals in the second quarter valued at approximately $109,000. Sei Investments Co. boosted its position in shares of Adamas Pharmaceuticals by 1,105.0% in the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after acquiring an additional 8,033 shares during the period. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Adamas Pharmaceuticals in the second quarter valued at approximately $184,000. 79.40% of the stock is owned by institutional investors.

Several equities analysts have commented on ADMS shares. Northland Securities started coverage on Adamas Pharmaceuticals in a report on Wednesday, November 29th. They set an “outperform” rating on the stock. BidaskClub downgraded Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 14th. Noble Financial reiterated a “buy” rating and set a $33.00 price target on shares of Adamas Pharmaceuticals in a report on Friday, September 29th. Mizuho reiterated a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, September 5th. Finally, Piper Jaffray Companies set a $52.00 price target on Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Adamas Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $45.67.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.watchlistnews.com/adamas-pharmaceuticals-inc-adms-insider-jennifer-j-rhodes-sells-440-shares/1776660.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.